Source: Annual Congress 2010 - Experimental pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Tofovic, V. Bilan, E. Jackson, O. Rafikova (Pittsburgh, United States Of America). Adenosine deaminase – adenosine pathway in hemolysis-induced pulmonary hypertension. Eur Respir J 2010; 36: Suppl. 54, 1079

Member's Comments

No comment yet.

Related content which might interest you: Phosphodiesterase inhibitors for the treatment of pulmonary hypertension Source: Eur Respir J 2008; 32: 198-209 Year: 2008 Adenosine 5’ – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in current smokers and patients with chronic obstructive pulmonary disease (COPD) Source: Eur Respir J 2003; 22: Suppl. 45, 414s Year: 2003 Activity of lysozyme and adenosine deaminase in patients with pulmonary tuberculosis Source: International Congress 2018 – Diagnosis of tuberculosis Year: 2018 Adenosine deaminase in the COPD pathogenesis in patients with pulmonary tuberculosis Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018 Effects of histamine and leukotriene antagonism on mannitol and adenosine monophosphate (AMP) challenge Source: Eur Respir J 2002; 20: Suppl. 38, 386s Year: 2002 PBF-680, an oral A1 adenosine receptor antagonist, inhibits adenosine monophosphate (AMP) airway hyperresponsiveness (AHR) in mild-to-moderate asthma: a Phase-IIa proof-of-concept trial Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 Role of PPARγ in pulmonary hypertension and the relationship between PPARγ and PKC Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases Year: 2009 Adenosine 5' – triphosphate (ATP) and adenosine 5' – monophosphate (AMP) challenge testing in healthy non-smokers and patients with mild asthma Source: Eur Respir J 2003; 22: Suppl. 45, 350s Year: 2003 Hypoxia causes permeability oedema in the constant-pressure perfused rat lung Source: Eur Respir J 2006; 27: 600-606 Year: 2006 Adenosine deaminase (ADA) in serum and pleural effusion Source: Eur Respir J 2006; 28: Suppl. 50, 581s Year: 2006 Hypoxia induced pulmonary hypertension – the role of dimethylarginine dimethylaminohydrolase 1 (DDAH-1) in acute and sustained hypoxic vasoconstriction Source: Annual Congress 2009 - Pulmonary circulation Year: 2009 The adenosine A2A-Receptor is not involved in adenosine induced bronchoconstriction in asthmatics Source: Eur Respir J 2003; 22: Suppl. 45, 103s Year: 2003 Tobacco smoke-induced emphysema and pulmonary hypertension – Role of NADPH oxidase NOX2 Source: Annual Congress 2010 - New mechanisms in lung development, acute and chronic lung diseases Year: 2010 New drugs for pulmonary hypertension Source: Eur Respir Mon 2012; 57: 233-246 Year: 2012 Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy Source: Eur Respir Rev 2009; 18: 35-41 Year: 2009 Pleural fluid and serum adenosine deaminase (ADA) activities reflects the severity of lung tuberculosis Source: Annual Congress 2008 - Diagnosis of tuberculosis: problems and perspectives Year: 2008 NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench Year: 2019 Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension Source: Eur Respir J 2009; 33: 1354-1360 Year: 2009 Beyond the dogma: novel β2-adrenoceptor signalling in the airways Source: Eur Respir J 2006; 27: 1286-1306 Year: 2006